Boston Scientific Corporation
BSX
$95.12
-$0.13-0.14%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 16.38% | 45.93% | 100.33% | 96.56% | 128.22% |
| Total Depreciation and Amortization | 6.10% | 4.84% | 5.77% | 5.93% | 5.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 59.92% | 130.28% | 36.31% | -16.11% | -30.56% |
| Change in Net Operating Assets | 40.00% | -122.43% | -133.73% | -17.02% | 23.38% |
| Cash from Operations | 37.24% | 24.78% | 23.86% | 39.63% | 64.02% |
| Capital Expenditure | -11.11% | -18.90% | -28.41% | -34.78% | -20.92% |
| Sale of Property, Plant, and Equipment | -25.00% | -83.33% | -66.67% | -71.43% | -66.67% |
| Cash Acquisitions | -156.21% | -97.94% | 18.46% | -232.51% | -17.44% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -364.29% | -490.24% | -239.47% | -226.37% | -154.90% |
| Cash from Investing | -120.94% | -78.17% | -4.27% | -157.87% | -28.00% |
| Total Debt Issued | -- | -- | 1,901.71% | 1,057.59% | -100.00% |
| Total Debt Repaid | -13,125.00% | -13,125.00% | -53,200.00% | -53,200.00% | 99.88% |
| Issuance of Common Stock | 26.37% | 19.02% | 17.86% | 35.37% | 33.82% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | 100.00% | 100.00% | 74.55% | 49.09% |
| Other Financing Activities | -67.59% | -63.51% | 31.96% | 67.78% | 68.75% |
| Cash from Financing | 36,180.00% | 18,044.44% | 825.00% | 368.90% | 100.91% |
| Foreign Exchange rate Adjustments | -175.00% | 140.00% | -50.00% | -22.22% | 55.56% |
| Miscellaneous Cash Flow Adjustments | -- | -- | 200.00% | -100.00% | -- |
| Net Change in Cash | -542.86% | 138.52% | 1,407.41% | 641.03% | 93.28% |